#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to recognize that cannabis use in older adults correlates with worse mental health outcomes, requiring systematic screening and counseling as part of comprehensive geriatric assessment. This evidence supports integrating cannabis use history into psychiatric and cognitive evaluations, particularly since older patients may not spontaneously disclose use due to stigma or lack of awareness about drug interactions with psychiatric medications.
A recent observational study identified an association between increasing cannabis use and worsening mental health outcomes in the general U.S. population, raising concerns about potential psychiatric adverse effects in patients who self-initiate or are considering cannabis therapy. The research underscores the importance of comprehensive mental health screening and baseline psychiatric assessment in patients presenting with cannabis use or requesting cannabis for medical indications, particularly given the rising prevalence of cannabis use across age groups including older adults. Clinicians should be aware that while cannabis may be used by some patients for anxiety or mood symptoms, epidemiologic evidence suggests regular use correlates with mental health deterioration, which could represent either a causal effect or confounding by underlying psychiatric disease. The findings are particularly relevant for geriatricians and other specialists managing complex older patients who may have comorbid psychiatric conditions or polypharmacy interactions with cannabinoid products. Practitioners should engage in shared decision-making conversations with patients about cannabis use that explicitly address mental health risks and include monitoring protocols for mood and anxiety changes during treatment. Clinicians should routinely assess psychiatric symptoms and baseline mental health status in any patient using or considering cannabis, with particular vigilance for mood worsening that may warrant dose reduction or discontinuation.
“What we’re seeing in clinical practice is that cannabis isn’t a monolith: the same plant affects different patients in fundamentally different ways, and age, genetics, and underlying psychiatric vulnerability matter enormously. When we see correlations between cannabis use and poor mental health outcomes, we have to ask whether cannabis is causing the problem or whether people with emerging psychiatric symptoms are self-medicating, because that distinction completely changes how we counsel our patients.”
💭 While observational studies linking cannabis use to poor mental health outcomes deserve clinical attention, healthcare providers should recognize that the directionality and causality of this association remain unclear—cannabis use may exacerbate existing mental health conditions, or individuals with untreated depression and anxiety may self-medicate with cannabis, confounding the relationship. The heterogeneity of cannabis products (varying THC/CBD ratios, delivery methods, and potency) and differences in user populations make it difficult to establish generalizable risk profiles, particularly in older adults where polypharmacy and age-related neurobiological changes may amplify any potential adverse effects. Additionally, many studies fail to adequately control for confounding variables such as concurrent alcohol or substance use, baseline psychiatric history, social isolation, or medical comorbidities that commonly co-occur in populations with both heavy cannabis use and mental health symptoms. Clinicians should maintain a thorough substance use history and consider
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: